Single-drug DCB Platform (Paclitaxel)
Vascular Disease (Proof-of-Concept)
Pre-clinicalCompleted with positive pre-clinical performance
Key Facts
Indication
Vascular Disease (Proof-of-Concept)
Phase
Pre-clinical
Status
Completed with positive pre-clinical performance
Company
About Advanced NanoTherapies
Advanced NanoTherapies is pioneering a nanotechnology-based drug delivery platform to revolutionize the treatment of vascular diseases. The company's core innovation is a drug-agnostic, biodegradable nanoparticle system that enables sustained, in-tissue release of synergistic drug combinations, starting with its SirPlux Duo DCB for CAD and PAD. Key achievements include an exclusive license from Cleveland Clinic, FDA Breakthrough Device Designation for below-the-knee (BTK) applications, and established strategic partnerships. A.N.T. aims to expand its platform beyond cardiovascular applications into neurology, ENT, and orthopedics.
View full company profileTherapeutic Areas
Other Vascular Disease (Proof-of-Concept) Drugs
| Drug | Company | Phase |
|---|---|---|
| Single-drug DCB Platform (Sirolimus) | Advanced NanoTherapies | Pre-clinical |